Protein predicts Gleevec resistance in gastrointestinal tumors
User rating: not rated yet
Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia.
Full story »
|

PhysOrg Forum
Video
Editorials
Free Magazines
Newsletter
Goto Archive
Suggest a story idea
Send feedback